Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) — The “Global Human Embryonic Stem Cell Market Analysis & Forecast 2024-2034: Market By Application; By End-user; and By Region” report has been added to ResearchAndMarkets.com’s offering.
The global human embryonic stem cell market is poised to undergo substantial growth, with a projected Compound Annual Growth Rate (CAGR) of 9.74% from 2024 to 2034. The market, which was valued at approximately USD 2.83 billion in 2023, is anticipated to escalate to an estimated USD 7.87 billion by the year 2034. This growth is fueled by a convergence of key drivers, including an increase in clinical trials, greater acceptance of stem cell therapies, augmented government funding for regenerative medicine, and the rising prevalence of both cardiac and malignant diseases requiring next-generation treatment solutions.
Key Market Segments Flourishing in Stem Cell Arena
The market is witnessing notable advancements across several segments. In stem cell biology research, there has been a substantial injection of funding, propelling this segment to generate the highest revenue within the sector in 2023. Technological strides and a growing demand for regenerative medicines, coupled with the steep increase in research & development activities, are projected to cultivate the fastest growth in this application segment.
End-User Demand Spearheading Market Development
End-users are fundamental to market progression, with the research segment claiming the highest financial ingress in 2023. The increase is attributed to the urgency to address chronic and genetic disorders via extensive stem cell studies. Concurrently, the clinical trials segment is forecasted to expand briskly, thanks to pioneering treatment developments, regulatory green lights, and a flourishing number of novel therapy trials.
Regional Landscape: North America and Asia Pacific Setting the Pace
Regionally, North America retains a dominant position due to its robust R&D ecosystem, significant disease burden, and hearty funding for therapy advancement. Meanwhile, the Asia Pacific market is set to experience the fastest growth, rising to meet the increased demand amid substantial government endorsements for research initiatives.
Geographically, the market spans regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed country-wise analysis encapsulated within the report. Key regions and countries are dissected to unravel market intricacies and potential opportunities that stakeholders and industry participants can capitalize on.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 145 |
| Forecast Period | 2023-2034 |
| Estimated Market Value (USD) in 2023 | $2.83 Billion |
| Forecasted Market Value (USD) by 2034 | $7.87 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
Companies Mentioned
- Thermo Fisher Scientific
- STEMCELL Technologies Inc.
- Merck KGaA
- PeproTech Inc.
- ViaCyte Inc.
- Takara Bio Inc.
- Astellas Pharma Inc.
- PromoCell GmbH
- Lineage Cell Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/3mu1l2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Human Embryonic Stem Cell Market
